Research programme: alpha-2 adrenoceptor modulators - Lundbeck

Drug Profile

Research programme: alpha-2 adrenoceptor modulators - Lundbeck

Alternative Names: Alpha2-adrenoceptor modulators research programme - Lundbeck

Latest Information Update: 25 Jul 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Lundbeck Research USA
  • Developer Procter & Gamble
  • Class
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Alpha 2 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 17 Mar 2003 Synaptic Pharmaceutical has been acquired by Lundbeck A/S
  • 07 Aug 2002 Preclinical trials in Undefined in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top